JERUSALEM (Reuters) – Israel-based Teva Pharmaceutical Industries reported as expected first-quarter profit and trimmed 2022 revenue estimates due to currency fluctuations.
The world’s largest generic drugmaker said on Tuesday it earned 55 cents per diluted share excluding one-time items in the January-March period, down from 63 cents a share a year earlier. Revenue fell 8% to $3.66 billion.
Analysts had forecast Teva would earn 55 cents a share ex-items on revenue of $3.76 billion, according to I/B/E/S data from Refinitiv.
Teva lowered its 2022 revenue estimate to $15.4-$16.0 billion from $15.6-$16.2 billion, after revenue of $15.9 billion in 2021. It previously projected 2022 adjusted EPS of $2.40-$2.60, versus $2.58 last year.
(Reporting by Steven Scheer; Editing by Ari Rabinovitch)
